Drugs / NUDT21 siRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06424301 | Dec 2024 → Sep 2025 overdue | retinoblastoma | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUDT21 siRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06424301 ↗ |
| Modality | Small interfering RNA (siRNA) | “a first-in-class siRNA-based drug targeting NUDT21” NCT06424301 ↗ |
| Route | Intravitreal | “Intravitreal injections of the targeted drug” NCT06424301 ↗ |
| Target | NUDT21 | “a first-in-class siRNA-based drug targeting NUDT21” NCT06424301 ↗ |